BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 12669727)

  • 21. Effects of age on prognosis with imatinib mesylate therapy for patients with Philadelphia chromosome-positive chronic myelogenous leukemia.
    Cortes J; Talpaz M; O'Brien S; Giles F; Beth Rios M; Shan J; Faderl S; Garcia-Manero G; Ferrajoli A; Wierda W; Kantarjian H
    Cancer; 2003 Sep; 98(6):1105-13. PubMed ID: 12973833
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Imatinib in combination with cytarabine for the treatment of Philadelphia-positive chronic myelogenous leukemia chronic-phase patients: rationale and design of phase I/II trials.
    Guilhot F; Gardembas M; Rousselot P; Tulliez M; Vigier M; Buzyn A; Rigal-Huguet F; Legros L; Michallet M; Berthou C; Najman A; Maloisel F; Mahon FX; Facon T; Berthaud P; Guilhot J;
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):92-7. PubMed ID: 12783382
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imatinib mesylate as treatment for blastic transformation of Philadelphia chromosome positive chronic myelogenous leukemia.
    Sureda A; Carrasco M; de Miguel M; Martínez JA; Conde E; Sanz MA; Díaz-Mediavilla J; Sierra J
    Haematologica; 2003 Nov; 88(11):1213-20. PubMed ID: 14607749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Usui N
    Gan To Kagaku Ryoho; 2005 Mar; 32(3):297-303. PubMed ID: 15791812
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel targeted therapies to overcome imatinib mesylate resistance in chronic myeloid leukemia (CML).
    Walz C; Sattler M
    Crit Rev Oncol Hematol; 2006 Feb; 57(2):145-64. PubMed ID: 16213151
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.
    Palandri F; Castagnetti F; Testoni N; Luatti S; Marzocchi G; Bassi S; Breccia M; Alimena G; Pungolino E; Rege-Cambrin G; Varaldo R; Miglino M; Specchia G; Zuffa E; Ferrara F; Bocchia M; Saglio G; Pane F; Alberti D; Martinelli G; Baccarani M; Rosti G;
    Haematologica; 2008 Dec; 93(12):1792-6. PubMed ID: 18838477
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Imatinib: new indication. New indications, but not robust evidence.
    Prescrire Int; 2008 Jun; 17(95):91-4. PubMed ID: 18623899
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Treatment of chronic myeloid leukemia with imatinib in the accelerated stage of the disease].
    Bulum J; Labar B; Mikulić M; Bogdanić V; Sertić D; Nemet D; Krecak-Gverić V; Kovacević J; Serventi-Seiwerth R; Mrsić-Davidović S; Zadro R; Boban D
    Lijec Vjesn; 2003; 125(7-8):176-9. PubMed ID: 14692090
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hematological and molecular response evaluation of CML patients on imatinib.
    Gupta A; Prasad K
    J Assoc Physicians India; 2007 Feb; 55():109-13. PubMed ID: 17571739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Imatinib in patients with newly diagnosed chronic-phase chronic myeloid leukemia.
    O'Brien SG; Deininger MW
    Semin Hematol; 2003 Apr; 40(2 Suppl 2):26-30. PubMed ID: 12783372
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sudden blast crisis in patients with Philadelphia chromosome-positive chronic myeloid leukemia who achieved complete cytogenetic remission after imatinib therapy.
    Alimena G; Breccia M; Latagliata R; Carmosino I; Russo E; Biondo F; Diverio D; Mancini M; Nanni M; Mandelli F
    Cancer; 2006 Sep; 107(5):1008-13. PubMed ID: 16878324
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Important therapeutic targets in chronic myelogenous leukemia.
    Kantarjian HM; Giles F; Quintás-Cardama A; Cortes J
    Clin Cancer Res; 2007 Feb; 13(4):1089-97. PubMed ID: 17317816
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imatinib mesylate in chronic myeloid leukemia: a prospective, single arm, non-randomized study.
    Deshmukh C; Saikia T; Bakshi A; Amare-Kadam P; Baisane C; Parikh P
    J Assoc Physicians India; 2005 Apr; 53():291-5. PubMed ID: 15987013
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Chronic myeloid leukemia patients resistant to or intolerant of interferon alpha and subsequently treated with imatinib show reduced immunoglobulin levels and hypogammaglobulinemia.
    Steegmann JL; Moreno G; Aláez C; Osorio S; Granda A; de la Cámara R; Arranz E; Reino FG; Salvanés FR; Fernández-Rañada JM; Muñoz C
    Haematologica; 2003 Jul; 88(7):762-8. PubMed ID: 12857554
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Imatinib therapy for patients with chronic myelogenous leukemia].
    Kawai Y; Ueda T
    Nihon Rinsho; 2004 Jul; 62(7):1325-31. PubMed ID: 15283151
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Chromosomal abnormalities in Philadelphia chromosome-negative metaphases appearing during imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase.
    Medina J; Kantarjian H; Talpaz M; O'Brien S; Garcia-Manero G; Giles F; Rios MB; Hayes K; Cortes J
    Cancer; 2003 Nov; 98(9):1905-11. PubMed ID: 14584073
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Imatinib mesylate (Glivec) in treatment of chronic phase chronic myeloid leukemia].
    Voglová J; Poznarová A; Chrobák L; Rabasová J; Beránek M; Moravcová J; Faber E; Klamová H; Cikhart M
    Vnitr Lek; 2004 Jan; 50(1):21-3, 26-9. PubMed ID: 15015226
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib in Philadelphia chromosome-positive chronic phase CML patients: molecular and cytogenetic response rates and prediction of clinical outcome.
    Le Coutre P; Kreuzer KA; Na IK; Schwarz M; Lupberger J; Holdhoff M; Baskaynak G; Gschaidmeier H; Platzbecker U; Ehninger G; Prejzner W; Huhn D; Schmidt CA
    Am J Hematol; 2003 Aug; 73(4):249-55. PubMed ID: 12879428
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Clonal evolution of abnormal Philadelphia chromosome-negative cells after imatinib mesylate therapy in patients with Philadelphia chromosome-positive chronic myelogenous leukemia].
    Jiang Q; Chen SS; Jiang B; Jiang H; Lu Y; Qiu JY; Lu DP
    Zhonghua Xue Ye Xue Za Zhi; 2005 Jan; 26(1):23-6. PubMed ID: 15946504
    [TBL] [Abstract][Full Text] [Related]  

  • 40. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia.
    Soverini S; Martinelli G; Rosti G; Bassi S; Amabile M; Poerio A; Giannini B; Trabacchi E; Castagnetti F; Testoni N; Luatti S; de Vivo A; Cilloni D; Izzo B; Fava M; Abruzzese E; Alberti D; Pane F; Saglio G; Baccarani M
    J Clin Oncol; 2005 Jun; 23(18):4100-9. PubMed ID: 15867198
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.